story of the week
Longitudinal Profiling Identifies Co-Occurring BRCA1/2 Reversions and TP53BP1, RIF1, and PAXIP1 Mutations in PARP Inhibitor–Resistant Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor resistant advanced breast cancer
Ann. Oncol 2024 Jan 18;[EPub Ahead of Print], E Harvey-Jones, M Raghunandan, L Robbez-Masson, L Magraner-Pardo, T Alaguthurai, A Yablonovitch, J Yen, H Xiao, R Brough, J Frankum, F Song, J Yeung, T Savy, A Gulati, J Alexander, H Kemp, C Starling, A Konde, R Marlow, M Cheang, P Proszek, M Hubank, M Cai, J Trendell, R Lu, R Liccardo, N Ravindran, A Llop-Guevara, O Rodriguez, J Balmana, N Lukashchuk, M Dorschner, L Drusbosky, I Roxanis, V Serra, S Haider, SJ Pettitt, CJ Lord, ANJ TuttFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.